Evidence map›Paper›PMID 40445564›Full record

ArticleRheumatology and therapy2025

The Lupus Check 5 Tool: A Practical Approach to Initiating Treatment Reviews in Systemic Lupus Erythematosus.

Anca Askanase, Antonis Fanouriakis, Lyra Agustin, Maria Dall'Era, Marta Mosca, Yoshiya Tanaka

Abstract read
In one paragraph

Article in Rheumatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anca AskanaseDepartment of Medicine, Columbia University Irving Medical Center, 630 W. 168th St., New York, NY, 10032, USA. ada20@cumc.columbia.edu.ORCID http://orcid.org/0000-0003-4597-5023
Antonis FanouriakisRheumatology and Clinical Immunology Unit, Attikon University Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece.ORCID http://orcid.org/0000-0003-2696-031X
Lyra AgustinBiopharmaceuticals Medical, AstraZeneca, Cambridge, UK.ORCID http://orcid.org/0009-0001-7585-5690
Maria Dall'EraDivision of Rheumatology, University of California San Francisco School of Medicine, San Francisco, CA, USA.
Marta MoscaRheumatology Unit, University of Pisa, Pisa, Italy.
Yoshiya TanakaFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.ORCID http://orcid.org/0000-0002-0807-7139

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the treatment landscape for systemic lupus erythematosus (SLE) has evolved in recent years, there is still a significant unmet need and many patients do not achieve key treatment goals, such as remission and low disease activity. Failure to reach these goals increases the risk of flare, organ damage accrual, and mortality in patients with SLE, and can have a significant impact on patient quality of life (QOL). While the importance of monitoring patients with SLE is highlighted across treatment recommendations, there is no clinical guidance on how to identify patients at risk of disease exacerbation and when to effectively initiate treatment reviews to improve their clinical outcomes. To address this, a panel of lupus experts have developed a clinical decision aid named the Lupus Check 5 Tool, which aims to identify patients in need of a treatment review through a simple five-question checklist. These questions cover a range of topics, including persistent glucocorticoid use, ongoing disease activity despite therapy, monitoring changes in laboratory values, flare frequency and severity, and the incorporation of the patient perspective and shared decision-making into clinical practice. Herein, we provide a detailed overview of the tool questions and the clinical evidence supporting their use to identify patients at risk of disease worsening. Use of the Lupus Check 5 Tool during each patient visit could facilitate timely alteration of therapy to help reduce disease activity, improve QOL, and work toward the long-term goals of remission and low disease activity.

Indexed as

Clinical managementSystemic lupus erythematosusTreatment review

Identifiers

PMID40445564
PMCPMC12246300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.